A Phase II Clinical Study of BW-20507 in Combination With PEG-IFN for the Treatment of Hepatitis B
Status:
NOT_YET_RECRUITING
Trial end date:
2028-05-08
Target enrollment:
Participant gender:
Summary
This is a randomized, open-label, multicenter phase II study to evaluate the efficacy and safety of BW-20507 in combination with PEG-IFN in CHB patients